Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05995366 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05995366 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 7 participants.
The verdict
NCT05995366, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the mass balance and safety of \[14C\] ABBV-903 in healthy male volunteers following a single oral dose administration.
Interventions
- DRUG ABBV-903
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-08-18 |
| Est. Completion | 2023-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05995366
The ClinicalTrials.gov registry entry for NCT05995366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABBV-903 is the first listed.
NCT05995366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05995366 about?
NCT05995366 is a clinical study titled "A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration". The purpose of this study is to evaluate the mass balance and safety of \[14C\] ABBV-903 in healthy male volunteers following a single oral dose administration.
What is the current status of trial NCT05995366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-08-18. Estimated completion is 2023-10-13.
What interventions are being tested in trial NCT05995366?
The interventions under investigation include: ABBV-903 (DRUG).
Who is sponsoring clinical trial NCT05995366?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.